Outsourced Pharma Capacity Update Videos - Large Molecule
-
Resilience Capabilities Update May 2026: Large Molecule
5/29/2026
An integrated network unites biologics, cell therapy, and drug product with digital systems and teams to speed tech transfer, scale reliably, and ensure delivery from development to commercial.
-
Rentschler Biopharma Capabilities Update May 2026: Large Molecule
5/29/2026
Rentschler Biopharma is a global leading contract development and manufacturing organization (CDMO) focused exclusively on client projects.
-
Samsung Biologics Capabilities Update May 2026: Large Molecule
5/28/2026
Watch this on-demand session to explore the future of global biologics manufacturing, dual-sourcing strategies, and next-generation expansion plans in advanced therapies.
-
Rezon Bio Capabilities Update May 2026: Large Molecule
5/28/2026
Discover how tailored biologics development strategies can improve scalability, reduce tech transfer risk, and create more reliable pathways from early development to commercial supply.
-
Alcami Capabilities Update May 2026: Large Molecule
5/28/2026
Watch this on-demand session to learn risk-based strategies for optimizing biologic drug substance-to-product transitions while minimizing aggregation and process stress.
-
Cytovance Biologics Capabilities Update March 2026: Large Molecule
3/17/2026
How a seasoned development and manufacturing team blends technical depth, reliability, and flexible support to advance large‑molecule programs amid shifting timelines, costs, and regulatory demands.
-
Fujifilm Biotechnologies Capabilities Update March 2026: Large Molecule
3/10/2026
An overview of manufacturing strategies and scaling options shows how aligned systems, smart planning, and flexible models support biologics from early development to commercialization.
-
ProBio Capabilities Update March 2026: Large Molecule
3/10/2026
A new Center of Excellence expands capacity for genetic‑medicine programs with upgraded facilities, streamlined workflows, and early‑stage services that support readiness for PD and IND milestones.
-
Boehringer Ingelheim Capabilities Update March 2026: Large Molecule
3/10/2026
Integrated culture and fermentation systems streamline development, improve scalability, and strengthen continuity throughout the lifecycle of complex biopharmaceutical programs.
-
Leveraging Advanced Tech, Proven Expertise From Cell Line Development And Beyond
1/28/2025
Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.